OBD Stock Overview
Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Oxford BioDynamics Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.091 |
| 52 Week High | UK£0.52 |
| 52 Week Low | UK£0.084 |
| Beta | 0.44 |
| 1 Month Change | -5.31% |
| 3 Month Change | -44.57% |
| 1 Year Change | -41.07% |
| 3 Year Change | -88.98% |
| 5 Year Change | -93.80% |
| Change since IPO | -94.28% |
Recent News & Updates
Recent updates
Here's Why We're Watching Oxford BioDynamics' (LON:OBD) Cash Burn Situation
Jan 18
Here's Why We're A Bit Worried About Oxford BioDynamics' (LON:OBD) Cash Burn Situation
Oct 08Is Oxford BioDynamics (LON:OBD) In A Good Position To Invest In Growth?
Sep 21Oxford BioDynamics (LON:OBD) Is In A Good Position To Deliver On Growth Plans
May 24We're Not Very Worried About Oxford BioDynamics' (LON:OBD) Cash Burn Rate
Dec 07Shareholder Returns
| OBD | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 2.1% | 2.2% | 2.7% |
| 1Y | -41.1% | -41.1% | 0.3% |
Return vs Industry: OBD matched the UK Life Sciences industry which returned -41.1% over the past year.
Return vs Market: OBD underperformed the UK Market which returned 0.3% over the past year.
Price Volatility
| OBD volatility | |
|---|---|
| OBD Average Weekly Movement | 10.9% |
| Life Sciences Industry Average Movement | 7.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: OBD's share price has been volatile over the past 3 months.
Volatility Over Time: OBD's weekly volatility has decreased from 26% to 11% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 45 | Jon Anthony Burrows | www.oxfordbiodynamics.com |
Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and the United Kingdom. The company provides EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation, and monitoring of 3D genomic biomarkers to diagnose patients. Its products include EpiSwitch Prostate Screening Test (PSE), a prostate cancer screening test; EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting therapeutic response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling.
Oxford BioDynamics Plc Fundamentals Summary
| OBD fundamental statistics | |
|---|---|
| Market cap | UK£18.39m |
| Earnings (TTM) | -UK£10.83m |
| Revenue (TTM) | UK£510.00k |
36.1x
P/S Ratio-1.7x
P/E RatioIs OBD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OBD income statement (TTM) | |
|---|---|
| Revenue | UK£510.00k |
| Cost of Revenue | UK£244.00k |
| Gross Profit | UK£266.00k |
| Other Expenses | UK£11.09m |
| Earnings | -UK£10.83m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.054 |
| Gross Margin | 52.16% |
| Net Profit Margin | -2,122.75% |
| Debt/Equity Ratio | 0% |
How did OBD perform over the long term?
See historical performance and comparison